Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib

BACKGROUND: A phase III randomized multicenter trial (ALTER0303) reported anlotinib to be significantly beneficial to patient survival. An array of inflammatory biomarkers, such as neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR), are associated with the response to treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tian, Song, Chao, Liang, Gaofeng, Xu, Xiaoyu, Wang, Chen, Zhang, Zhanchun, Tang, Mengqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958089/
https://www.ncbi.nlm.nih.gov/pubmed/35356064
http://dx.doi.org/10.1155/2022/5879137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958089/
https://www.ncbi.nlm.nih.gov/pubmed/35356064
http://dx.doi.org/10.1155/2022/5879137

Ejemplares similares